1 The aim of this study was to compare the systemic bioactivity of low and high doses of inhaled budesonide and fluticasone propionate given by respective dry powder inhaler devices. 2 A randomised, single blind cross-over design was used in nine healthy subjects who were given 800 ,ug day-1 of budesonide Turbohaler (Bsoo) for 1 week, followed by 1 week of 1600 ig day-1 (BI600), or fluticasone Diskhaler 750 jg day-1 (F750) for 1 week followed by 1 week of 1500 pg day-1 (F1500). There was a 1 week washout between treatments with fluticasone or budesonide. A twice daily dosing regime was used and mouth-rinsing was employed to reduce gut bioavailability as well as to obviate local adverse effects. 
Introduction
The use of high dose inhaled corticosteroids, is now benefit ratio of inhaled corticosteroids is determined well-established in the management of chronic by their relative potencies for topical (airway) and asthma [1] . Their increasing use has lead to concern systemic glucocorticoid activity. Using the Mackenover the potential systemic adverse effects, and in zie skin vasoconstrictor assay it has been shown that this respect uncertainty remains regarding the extent budesonide and fluticasone propionate exhibit equivaand clinical relevance of these effects [2] . The risklent topical anti-inflammatory potency [3] , both being approximately two-fold more potent than beclomethasone dipropionate [4, 5] . There are however, doubts as to how this method relates to airway or systemic glucocorticoid activity. The systemic effects of inhaled steroids may arise from the absorption of the drug from the oropharynx, from the gut after swallowing, as well as from the lung vascular-bed. In terms of oral bioavailability budesonide and fluticasone undergo extensive first-pass hepatic metabolism after absorption from the gut. The oral systemic bioavailability of budesonide has been calculated as being 11% [6] and that for fluticasone as 1% [7] . In view of this extensive first-pass hepatic metabolism, absorption across the lung vascular-bed assumes relatively more importance in determining the propensity for systemic effects because there is no pulmonary first-pass metabolism of either budesonide or fluticasone. The latter will in turn be influenced by factors affecting lung deposition of the drug including the degree of peripheral airway narrowing and the type of delivery device. The relative importance of absorption from the lung can be increased further by reducing gastrointestinal absorption with mouth-rinsing after dosing [8] .
We have therefore, for the first time compared the systemic bioactivity of low and high doses of budesonide and fluticasone, given by respective dry powder inhaler devices. Normal volunteers were used to avoid possible confounding effects of previous exposure to oral or inhaled corticosteroids, as well as to obviate the effects of abnormal airway geometry on peripheral lung deposition and hence systemic absorption with different inhaler delivery devices. It was also decided to employ mouth-rinsing in order to reduce oral bioavailability as far as possible, and also to minimise local adverse effects.
Methods

Subjects
Nine (four females) healthy, non-smoking subjects, mean (s.e. mean) age 21 (0.35) years, completed the study. None of the subjects was on regular medication and all had a normal physical examination, an FEVI greater than 90% of predicted, and normal serum electrolytes, calcium, phosphate and alkaline phosphatase. The study was approved by the local Ethics Committee and subjects gave written informed consent.
Protocol
A single (investigator) blind, randomised, crossover design was used. After baseline measurements (Bo or Fo) subjects received budesonide 800 pg day-' (Bsoo) [ At each visit subjects were examined for the presence of oral candidiasis and questioned regarding the occurrence of dysphonia or sore throat.
Assays
Serum cortisol was measured using a commercial radio-immunoassay (r.i.a.) kit (Incstar, Wokingham, Berkshire). The coefficients of variability (c.v.) for analytical imprecision within and between assays were 9.4% and 6.6% respectively. The normal reference range for morning cortisol is 193-690 nmol l-l. Plasma osteocalcin was assayed using r.i.a. (Incstar) with an intra-assay C.V. of 4.37%, and a normal reference range of 1.8-6.6 ng ml-'. Plasma alkaline phosphatase, serum and urinary calcium and serum phosphate, were analysed using automated spectrophotometry (Cobas Bio, Hoffman La Roche, USA). The normal reference range for alkaline phosphatase is 98-279 iu 1-1, and the intra-assay and interassay C.V. were 0.3% and 2.84% respectively. Serum calcium had a reference range of 2.02-2.60 mmol 1-' and intra-assay and interassay c.v. of 1.22% and 1.03% respectively. The reference range for serum phosphate is 0.87-1.45 mmol 1-1 with inter-and intraassay c.v. of 0.9% and 2.4%. The assay for fasting urinary calcium had intra-and interassay C.V. of 1.20% and 1.22% respectively.
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Statistical analysis Data was analysed using a 'Statgraphics' software package (STSC Software Group, Rockville, Maryland, USA).
The power of the study was based on the ability to detect a mean difference of 60 nmol (Figure la) , whilst the lower doses of both drugs significantly (P < 0.05) attenuated the post-tetracosactrin cortisol level (Table 1 ). There was no significant difference between the low and high doses of each treatment or between the two drugs (Figure lb) .
Bone metabolism
There were no significant changes in plasma osteocalcin during low or high doses of either drug compared with baseline ( A similar, but non-significant trend in alkaline phosphatase has, however been noted previously [9, 10] using similar doses of inhaled budesonide. It is important to appreciate that whilst the rise in alkaline phosphatase was statistically significant, the levels 530 A. Grove et al. NS remained within the normal range in all cases. Furthermore, if budesonide was suppressing bone formation, alkaline phosphatase, a marker of osteoblast function would be expected to fall as has been shown in subjects taking oral prednisolone [9] . It is possible that an increase in alkaline phosphatase could represent an effect of budesonide on the liver isoenzyme. Budesonide also produced a significant rise in serum phosphate, within the normal range, compared with the value at Bo. Again Bo was significantly lower than Fo for this parameter, although a previous study reported by Toogood and co-workers show that budesonide produced a rise in serum phosphate by increasing the tubular resorbtion of phosphate [11] . The significant fall in fasting urinary calcium with high dose treatment is consistent with the findings of Toogood et al. where night-time hypocalciuria occurred along with an increase in the maximum tubular resorbtion of calcium [11] .
The pattern of HPA axis suppression seen in this study, namely attenuation of the post tetracosactrin cortisol is in agreement with a previous study by Brown et al. [12] where the post tetracosactrin serum cortisol appeared to be more sensitive and specific than early morning cortisol in terms of detecting suppression, in asthmatic patients taking high dose inhaled steroids. In this respect Brown and co-workers found that 24 h urinary free cortisol and the short tetracasactrin test had equivalent sensitivity at detecting adrenal suppression [12] . We did not perform repeated hourly plasma cortisol sampling over the duration of each study day, because the response to tetracosactrin would have invalidated any subsequent cortisol measurements. We believe that the measurement of the tetracosactrin cortisol response more closely mimics the physiological stress response than the use of unstimulated plasma cortisol or urinary free cortisol. Furthermore, in our own experience, we have previously found the measurement of 24 h urinary free cortisol excretion to be less reliable than the short tetracosactrin response. Osteocalcin appears to be the most sensitive parameter of bone metabolism being significantly suppressed when alkaline phosphatase, urinary hydroxyproline and calcium excretion are unaltered [9, 13, 14] . Interestingly, we found that fasting urinary calcium, and not osteocalcin was significantly altered by high-dose inhaled steroid.
In this study, where gut absorption was minimised as far as possible by mouth rinsing, we were still able to show a significant attenuation of serum cortisol response to tetracosactrin thus emphasising the importance of absorption from the lung vascular-bed in determining systemic bioactivity. This is supported by the findings of two previous studies. Firstly, Selroos et al. showed that mouth rinsing reduced the systemic bioavailability of inhaled budesonide delivered by Turbohaler by approximately 15%, as assessed by suppression of early morning cortisol [8] .
In a pharmacokinetic study with the budesonide Turbohaler, using the charcoal-block technique, it was shown that the oral bioavailability of inhaled budesonide was in the order of 20% [15] . The importance of lung bioavailability for fluticasone is also supported by data from Bain et al. [16] , who using r.i.a. demonstrated significant circulating plasma levels of fluticasone following 1000 pg from a metered dose inhaler, with a profile consistent with lung rather than gut absorption.
Data from two different radiolabelled deposition studies have shown the Turbohaler to produce 27% lung deposition and the Diskhaler 12% deposition [17, 18] . Thus, when correcting for differences in lung deposition between the two devices, it would appear that fluticasone may exhibit greater systemic bioactivity that budesonide on a microgram equivalent basis. This hypothesis is supported by a single-dosing study of 250 pg, 500 jig and 1000 pg doses of fluticasone propionate Diskhaler compared with a single 800 pg dose of budesonide Turbohaler, both taken with mouth rinsing in normal volunteers [19] . Fluticasone propionate produced dose-related suppression of the area under the plasma cortisol versus time curve for 0 to 20 h (AUCO-20). The percentage suppression from placebo was 8% for fluticasone 250 pg, 18% for fluticasone 500 pg and 29% for fluticasone 1000 jig; in comparison with 16% for budesonide 800 jig. A further evaluation after seven doses of fluticasone 1000 jig twice daily resulted in a 66% suppression of cortisol AUCO-20. Clearly, studies comparing equivalent doses of the two drugs administered by the same device, such as a metered-dose inhaler or spacer, are therefore required in order to further investigate this issue.
Larger multicentre studies in asthmatics have compared high doses of fluticasone propionate and beclomethasone dipropionate given by metered-dose inhaler, and have yielded conflicting results regarding relative systemic bioactivity. No differences were found between fluticasone propionate and beclomethasone dipropionate both given at a dose of 1500 pg day-', in terms of morning plasma cortisol, tetracosactrin response and urinary free cortisol [20] . In contrast, Bakke et al. reported a fall in plasma cortisol from 360 nmol 1-1 to 226 nmol 1-l and in ACTH from 34 ng 1-l to 22 ng 1-1 with fluticasone propionate 2000 jig day-1, whereas no suppression was detected with beclomethasone dipropionate 1600 jig day-I [21] . Barnes and colleagues showed a 1.3 fold greater dose-ratio for plasma cortisol suppression with beclomethasone dipropionate, despite a two-fold difference in dose between fluticasone propionate 1000 jig day-l and beclomethasone dipropionate 2000 jig day-' [22] . Thus, if as has been suggested, that fluticasone propionate has greater airway glucocorticoid potency then beclomethasone dipropionate or budesonide, it is perhaps not surprising to find that it also has greater systemic glucocorticoid potency, on a microgram equivalent basis.
Although this study, using normal subjects can be seen to represent an in vivo bioassay for the systemic effects of inhaled corticosteroids, it clearly has limitations which need to be addressed. The biochemical indices of bone turnover used are at best only surrogate parameters of bone turnover, and it is therefore necessary to design propsective studies in asthmatics, monitoring bone density itself. However, the difficulties of performing prospective studies in asthmatics in terms of confounding effects of exposure to pre-vious inhaled and oral corticosteroids are wellrecognised [2] . Furthermore, the altered geometry of asthmatic airways may affect the pulmonary deposition of drugs, an effect that may vary with the type of inhaler device used, in turn making extrapolation from studies in normal subjects difficult.
